

ForPatients

by Roche

Non-Small Cell Lung Cancer (NSCLC)

An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib

Trial Status

Active, not recruiting

Trial Runs In

24 Countries

Trial Identifier

NCT04764188 MO42122

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study aims to characterize the clinical management and outcomes of participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who are being treated with alectinib in real-world clinical practice.

Hoffmann-La Roche

Sponsor

N/A

Phase

NCT04764188 MO42122

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

>=18 Years

Healthy Volunteers

No
